Search

Search Results
Results 3551 - 3560 of 8494 for Skin Cancer
  • Psoriasis trial enters final stage
    News - 4 Nov 2004
    Solbec Pharmaceuticals Ltd today announced the successful completion of the first two stages of the Phase I clinical trial of its lead compound, CoramsineTM (SBP002), for the treatment of psoriasis.
  • Iressa
    Drug - 19 Dec 2025
    Consumer Medicine Information (CMI) about Iressa intended for persons living in Australia.
  • Kliovance
    Drug - 18 Dec 2025
    Consumer Medicine Information (CMI) about Kliovance intended for persons living in Australia.
  • Kliogest
    Drug - 18 Dec 2025
    Consumer Medicine Information (CMI) about Kliogest intended for persons living in Australia.
  • Estrofem
    Drug - 18 Dec 2025
    Consumer Medicine Information (CMI) about Estrofem intended for persons living in Australia.
  • Tecvayli
    Drug - 18 Dec 2025
    Consumer Medicine Information (CMI) about Tecvayli intended for persons living in Australia.
  • Talvey
    Drug - 16 Dec 2025
    Consumer Medicine Information (CMI) about Talvey intended for persons living in Australia.
  • Fragmin
    Drug - 16 Dec 2025
    Consumer Medicine Information (CMI) about Fragmin intended for persons living in Australia.
  • Tomudex
    Drug - 15 Dec 2025
    Consumer Medicine Information (CMI) about Tomudex intended for persons living in Australia.
  • Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children
    News - 12 Dec 2025
    Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to...

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback